ABUS — Arbutus Biopharma Corp
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1447028 ·
Last close
$4.22
Market Cap
$836.01M
52W High
$5.45
52W Low
$3.50
ADV30
6,864,926
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,014,000 | — | -5,751,000 | -5,143,000 | 274,025,000 | 19,171,000 | 15,292,000 |
| Mar 2026 | 179,126,000 | — | 169,117,000 | 169,695,000 | 277,164,000 | 23,706,000 | 16,987,000 |
| Dec 2025 | 1,051,000 | — | -7,644,000 | -3,756,000 | 94,618,000 | 18,008,000 | 18,042,000 |
| Sep 2025 | 529,000 | — | -8,293,000 | -7,742,000 | 97,710,000 | 22,408,000 | 20,311,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-34,356,000
Investing CF
$6,431,000
Financing CF
$14,556,000
CapEx
$-86,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.71
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,210,378,000
Inventory
—
Receivables
$180,053,000
ST Investments
$71,520,000
EBIT TTM
$160,806,000
Pretax Income TTM
$160,720,000
Interest Exp TTM
$86,000
Analysts
1
Yahoo Snapshot (yfinance, live)
Total Revenue
$181,720,000
EBITDA
$147,472,992
Free Cash Flow
$-80,236,376
Enterprise Value
$923,980,928
Total Cash
$92,625,000
Total Debt
$3,625,000
Shares Out
198,105,743
Trailing EPS
$0.79
Book Value
$1.31
ROE
89.6%
ROA
48.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 14,083,000 | -27,051,000 | -33,501,000 | 94,618,000 | 18,042,000 | 76,576,000 | -39,637,000 |
| Dec 2024 | 6,171,000 | -69,974,000 | -69,920,000 | 131,707,000 | 34,341,000 | 97,366,000 | -64,850,000 |
| Dec 2023 | 18,141,000 | -78,034,000 | -72,849,000 | 144,401,000 | 38,383,000 | 106,018,000 | -85,936,000 |
| Dec 2022 | 39,019,000 | -63,223,000 | -69,456,000 | 195,419,000 | 58,567,000 | 136,852,000 | -35,356,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$191,445,000
NetIncome TTM
$160,720,000
OpCashFlow TTM
—
Assets (Latest)
$277,164,000
Forward EPS
$-0.17
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| ARDX | ARDELYX, INC. | $846.86M | $3.28 | — |
| AVBP | ArriVent BioPharma, Inc. | $824.92M | $16.73 | — |
| HELP | Helus Pharma Inc. | $862.11M | $11.80 | — |
| PAHC | PHIBRO ANIMAL HEALTH CORP | $808.34M | $38.30 | — |
| OBX | Obsidian Therapeutics, Inc. | $803.05M | $13.00 | — |
News headlines (Yahoo Finance, 1h cache)
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
2026-10-01 11:30 · Yahoo
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
2026-09-30 11:30 · Yahoo
Arbutus Biopharma shares jump after unveiling $230 million share buyback plan
2026-08-21 13:32 · Yahoo
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
2026-08-21 11:30 · Yahoo
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
2026-08-11 00:18 · Yahoo
Arbutus, Sanofi escalate mRNA patent fights; InnoCare’s TYK2 contender advances
2026-07-17 10:07 · Yahoo
ABUS Stock On Track For Best Day In About Two Months — What’s The Moderna Connection?
2026-07-16 18:41 · Yahoo
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to
2026-07-16 11:30 · Yahoo
Arbutus Biopharma (ABUS) Joins Russell Defensive Indexes And Exits Value Benchmarks
2026-07-09 22:11 · Yahoo
ABUS Stock Rallies Ahead Of Big Payout From Moderna Settlement This Week
2026-07-07 18:28 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.